The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer: Clinical and pathological factors influencing it

Yuya Nogami, Kouji Banno, Haruko Irie, Miho Iida, Iori Kisu, Yohei Masugi, Kyoko Tanaka, Eiichirou Tominaga, Shigeo Okuda, Koji Murakami, Daisuke Aoki

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: We studied the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in cervical and endometrial cancers with particular focus on lymph node metastases. Methods: Seventy patients with cervical cancer and 53 with endometrial cancer were imaged with 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography before lymphadenectomy. We evaluated the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography using the final pathological diagnoses as the golden standard. Results: We calculated the sensitivity, specificity, positive predictive value and negative predictive value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. In cervical cancer, the results evaluated by cases were 33.3, 92.7, 55.6 and 83.6%, respectively. When evaluated by the area of lymph nodes, the results were 30.6, 98.9, 55.0 and 97.0%, respectively. As for endometrial cancer, the results evaluated by cases were 50.0, 93.9, 40.0 and 95.8%, and by area of lymph nodes, 45.0, 99.4, 64.3 and 98.5%, respectively. The limitation of the efficacy was found out by analyzing it by the region of the lymph node, the size of metastatic node, the historical type of tumor in cervical cancer and the prevalence of lymph node metastasis. Conclusion: The efficacy of positron emission tomography/computed tomography regarding the detection of lymph node metastasis in cervical and endometrial cancer is not established and has limitations associated with the region of the lymph node, the size of metastasis lesion in lymph node and the pathological type of primary tumor. The indication for the imaging and the interpretation of the results requires consideration for each case by the pretest probability based on the information obtained preoperatively.

Original languageEnglish
Article numberhyu161
Pages (from-to)26-34
Number of pages9
JournalJapanese Journal of Clinical Oncology
Volume45
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Endometrial Neoplasms
Uterine Cervical Neoplasms
Lymph Nodes
Neoplasm Metastasis
Deoxyglucose
Positron Emission Tomography Computed Tomography
Lymph Node Excision
Neoplasms
Sensitivity and Specificity

Keywords

  • Clinical oncology
  • Diagnostic imaging
  • Gynecology
  • Lymphatic metastasis
  • Positron-emission tomography

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

@article{89f31ebe144a4ca9b136b0e426a907e3,
title = "The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer: Clinical and pathological factors influencing it",
abstract = "Objective: We studied the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in cervical and endometrial cancers with particular focus on lymph node metastases. Methods: Seventy patients with cervical cancer and 53 with endometrial cancer were imaged with 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography before lymphadenectomy. We evaluated the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography using the final pathological diagnoses as the golden standard. Results: We calculated the sensitivity, specificity, positive predictive value and negative predictive value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. In cervical cancer, the results evaluated by cases were 33.3, 92.7, 55.6 and 83.6{\%}, respectively. When evaluated by the area of lymph nodes, the results were 30.6, 98.9, 55.0 and 97.0{\%}, respectively. As for endometrial cancer, the results evaluated by cases were 50.0, 93.9, 40.0 and 95.8{\%}, and by area of lymph nodes, 45.0, 99.4, 64.3 and 98.5{\%}, respectively. The limitation of the efficacy was found out by analyzing it by the region of the lymph node, the size of metastatic node, the historical type of tumor in cervical cancer and the prevalence of lymph node metastasis. Conclusion: The efficacy of positron emission tomography/computed tomography regarding the detection of lymph node metastasis in cervical and endometrial cancer is not established and has limitations associated with the region of the lymph node, the size of metastasis lesion in lymph node and the pathological type of primary tumor. The indication for the imaging and the interpretation of the results requires consideration for each case by the pretest probability based on the information obtained preoperatively.",
keywords = "Clinical oncology, Diagnostic imaging, Gynecology, Lymphatic metastasis, Positron-emission tomography",
author = "Yuya Nogami and Kouji Banno and Haruko Irie and Miho Iida and Iori Kisu and Yohei Masugi and Kyoko Tanaka and Eiichirou Tominaga and Shigeo Okuda and Koji Murakami and Daisuke Aoki",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/jjco/hyu161",
language = "English",
volume = "45",
pages = "26--34",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer

T2 - Clinical and pathological factors influencing it

AU - Nogami, Yuya

AU - Banno, Kouji

AU - Irie, Haruko

AU - Iida, Miho

AU - Kisu, Iori

AU - Masugi, Yohei

AU - Tanaka, Kyoko

AU - Tominaga, Eiichirou

AU - Okuda, Shigeo

AU - Murakami, Koji

AU - Aoki, Daisuke

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: We studied the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in cervical and endometrial cancers with particular focus on lymph node metastases. Methods: Seventy patients with cervical cancer and 53 with endometrial cancer were imaged with 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography before lymphadenectomy. We evaluated the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography using the final pathological diagnoses as the golden standard. Results: We calculated the sensitivity, specificity, positive predictive value and negative predictive value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. In cervical cancer, the results evaluated by cases were 33.3, 92.7, 55.6 and 83.6%, respectively. When evaluated by the area of lymph nodes, the results were 30.6, 98.9, 55.0 and 97.0%, respectively. As for endometrial cancer, the results evaluated by cases were 50.0, 93.9, 40.0 and 95.8%, and by area of lymph nodes, 45.0, 99.4, 64.3 and 98.5%, respectively. The limitation of the efficacy was found out by analyzing it by the region of the lymph node, the size of metastatic node, the historical type of tumor in cervical cancer and the prevalence of lymph node metastasis. Conclusion: The efficacy of positron emission tomography/computed tomography regarding the detection of lymph node metastasis in cervical and endometrial cancer is not established and has limitations associated with the region of the lymph node, the size of metastasis lesion in lymph node and the pathological type of primary tumor. The indication for the imaging and the interpretation of the results requires consideration for each case by the pretest probability based on the information obtained preoperatively.

AB - Objective: We studied the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in cervical and endometrial cancers with particular focus on lymph node metastases. Methods: Seventy patients with cervical cancer and 53 with endometrial cancer were imaged with 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography before lymphadenectomy. We evaluated the diagnostic performance of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography using the final pathological diagnoses as the golden standard. Results: We calculated the sensitivity, specificity, positive predictive value and negative predictive value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. In cervical cancer, the results evaluated by cases were 33.3, 92.7, 55.6 and 83.6%, respectively. When evaluated by the area of lymph nodes, the results were 30.6, 98.9, 55.0 and 97.0%, respectively. As for endometrial cancer, the results evaluated by cases were 50.0, 93.9, 40.0 and 95.8%, and by area of lymph nodes, 45.0, 99.4, 64.3 and 98.5%, respectively. The limitation of the efficacy was found out by analyzing it by the region of the lymph node, the size of metastatic node, the historical type of tumor in cervical cancer and the prevalence of lymph node metastasis. Conclusion: The efficacy of positron emission tomography/computed tomography regarding the detection of lymph node metastasis in cervical and endometrial cancer is not established and has limitations associated with the region of the lymph node, the size of metastasis lesion in lymph node and the pathological type of primary tumor. The indication for the imaging and the interpretation of the results requires consideration for each case by the pretest probability based on the information obtained preoperatively.

KW - Clinical oncology

KW - Diagnostic imaging

KW - Gynecology

KW - Lymphatic metastasis

KW - Positron-emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84922378194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922378194&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu161

DO - 10.1093/jjco/hyu161

M3 - Article

C2 - 25368102

AN - SCOPUS:84922378194

VL - 45

SP - 26

EP - 34

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

M1 - hyu161

ER -